Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant

Table 5

Subgroup analysis of the impact of the preswitch VA (< or ≥70 letters) on VA.

	Preswitch visual acuity
	VA < 70 letters (group 1)	VA ≥ 70 letters (group 2)	value^a (comparison between groups 1 and 2)
Number of eyes	17	8
Mean letter score at baseline prior to any injection (SD)	48.1 (17.2)	63.9 (7.9)	0.007
Mean letter score preswitch (SD)	47.4 (15.8)	77.7 (5)	0.001
Mean letter score postswitch M3 (SD)	59 (15.8)	79.4 (5.3)	0.001
Mean letter score postswitch M6 (SD)	58 (13)	80.1 (5.6)	0.001
Mean VA change from preswitch (SD)	10.6 (17.4)	2.4 (5.7)	0.2
F	5.6	15.37
value (ANOVA test)	0.004	0.03
value^b (comparison between VA preswitch and M6 within each group)	0.02	0.5

ANOVA test was performed to assess significance between VA at baseline, preswitch, M3, and M6 after switch to aflibercept within each group. ^a values were obtained after an unpaired nonparametric Mann–Whitney test between groups 1 and 2 at each time point. ^b values were obtained after an paired nonparametric Wilcoxon test between preswitch VA and VA at M6. VA: visual acuity. <0.05; <0.01; and <0.001.